Adverse drug reactions of GLP-1 agonists: A systematic review of case reports

Rashmi Shetty, Fathima Thashreefa Basheer, Pooja Gopal Poojari, Girish Thunga, Viji Pulikkel Chandran, Leelavathi D. Acharya

Research output: Contribution to journalReview articlepeer-review

22 Citations (Scopus)


Background and aim: The importance of glucagon-like peptide-1 (GLP-1) agonists is increasing because of its blood sugar controlling and weight loss properties. The data regarding safety of GLP-1 agonists are limited. This study aims to review case reports and case series on adverse drug reactions (ADRs) of GLP-1 agonist. Methodology: A comprehensive search was performed in PubMed/Medline, Scopus and Embase to identify literatures. Bibliographic search and open search in Google, Google Scholar, SpringerLink and ResearchGate was performed to identify additional studies. Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study. Reviews, experimental studies, observational studies, grey literature and non English studies were excluded. Results: The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide – 46, exenatide – 46, dulaglutide – 20, semaglutide – 4, albiglutide – 2, lixisenatide – 2). The major ADRs reported was gastrointestinal disorders (n = 40) followed by renal (n = 23), dermatologic (n = 14), hepatic (n = 10), immunologic (n = 13), endocrine/metabolic (n = 7), hematologic (n = 3), angioedema (n = 3), neurologic (n = 2), cardiovascular (n = 2) and 1 from each of psychiatric, reproductive, generalized edema problems. Conclusion: Gastrointestinal problems, particularly pancreatitis was the more frequently reported adverse drug reaction associated with GLP-1 agonist. The most adverse drug reactions were observed with liraglutide and exenatide.

Original languageEnglish
Article number102427
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Issue number3
Publication statusPublished - 03-2022

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Adverse drug reactions of GLP-1 agonists: A systematic review of case reports'. Together they form a unique fingerprint.

Cite this